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groups were investigated: (1) The effect of NK depletion (with the
depleting antibody, PK136) on engraftment and tolerance was
determined. (2) The effect of NK depletion on engraftment efﬁ-
ciency was tested by transplanting in the presence or absence of
busulfan. (3) We determined if blocking NK signalling with the
anti-adhesion antibody anti-LFA1 could produce effects on en-
graftment similar to those observed with whole-scale NK deple-
tion. Results: (1) Animals with unmanipulated NK cells exhibited
costimulation-blockade resistant rejection when transplanted with
5  106 donor cells. However, NK depletion promoted stable
chimerism even when very low doses of donor marrow (0.5  106)
were infused. The chimeric animals in both the NK replete and
NK-depleted groups were tolerant to their allografts: they exhib-
ited deletion of donor-reactive v5 and v8 CD4 cells and
accepted Balb/C skin grafts. (2) NK depletion had a powerful effect
on engraftment efﬁciency: NK depletion promoted engraftment
even in the absence of busulfan. (3) Blocking NK function with the
anti-LFA1 antibody had the same effect as whole-scale NK deple-
tion with PK136: treated animals became stably chimeric and
tolerant even when very low doses of donor marrow were infused.
Implications: These data highlight the central role that NK cells
play in rejection of allogeneic bone marrow and underscores the
need to control NK alloreactivity during clinical transplantation.
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A MULTI-INSTITUTIONAL STUDY OF EXTRACORPOREAL PHOTOIM-
MUNE THERAPY (ECP) WITH UVADEX FOR THE PREVENTION OF
ACUTE GVHD IN PATIENTS (PTS) UNDERGOING STANDARD MYELOA-
BLATIVE CONDITIONING AND ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION (AHCT)
Abhyankar, S.1; Shaughnessy, P.J.2; Bolwell, B.J.3; van Besien, K.4;
Mistrik, M.5; Grigg, A.6; Dodds, A.7; Prince, H.M.8; Machado, A.9;
Thienel, U.10; Wang, J.10; Foss, F.11; Apperley, J.12, The Photopheresis
Study Group. 1. Kansas City Cancer Center, Kansas City, MO; 2. Texas
Transplant Institute, San Antonio, TX; 3. The Cleveland Clinic Foun-
dation, Cleveland, OH; 4. University of Chicago, Chicago, IL; 5. Klinika
Hematologie a Transfuziologie, Bratislavia, Slovakia (Slovak Republic);
6. Royal Melbourne Hospital, Melbourne, Australia; 7. St. Vincents
Hospital, Sydney, Australia; 8. Peter MacCallum Cancer Institute, East
Melbourne, Australia; 9. Instituto Portugues de Oncologia de Francisco
Gentil, Lisbon, Portugal; 10. Therakos, Exton, PA; 11. New England
Medical Center, Boston, MA; 12. Hammersmith Hospital Imperial
College School of Medicine, London, United Kingdom.
ECP with UVADEX has shown beneﬁt in pts with acute and
chronic GVHD. ECP has shown to reduce the incidence of
GVHD in a reduced intensity conditioning regiment (Foss. BMT.
2004 May). We report preliminary results of the ﬁrst multi-insti-
tutional phase 2 study examining ECP with a standard myeloab-
lative preparative regimen prior to AHCT. ECP was given on 2
consecutive days between D-10 and D-6, followed by cyclophos-
phamide 60 mg/kg/day for 2 days and TBI 1200 cGy over 3 days.
GVHD prophylaxis was Cyclosporine 3–5 mg/kg IV daily begin-
ning D-1, and later switched to PO, adjusted to keep levels 200–
600 ng/ml, and methotrexate 10 mg/m2 on D1, 3, 6, and 11 for pts
who had matched unrelated donors (MUD) or HLA class 1 one-
antigen mismatched related donors (MMRD), or 10 mg/m2 on D1
and 5 mg/m2 on D3, 6, and 11 for pts who had matched related
donors (MRD). Enrollment has been completed and data are
available on 61 of 65 pts. The median age was 39 (20–60) years and
40 (66%) pts were male. Diagnoses included AML/MDS (n20),
ALL (n14), CML (n16), lymphoma (n5), CLL (n3), and
other (n3). 29 pts had MRD, 31 MUD, and 1 MMRD. 28 pts
received bone marrows and 33 patients had PBPC for their trans-
plant. All patients engrafted. Acute GVHD grade 2–4 occurred in
11 (37.9%) pts and grade 3–4 occurred in 2 (7%) pts, who received
MRD transplants (n29); and grade 2–4 in 16 (51.6%) pts and
grade 3–4 in 10 (32.3%) pts, who received MUD transplants
(n31). No aGVHD occurred in 1 pt who received a MMRD
transplant. Mild reversible hypotension related to ECP occurred in
1 pt who was able to continue on study. Chronic GVHD occurred
in 23 of 61 evaluable pts; limited in 15, extensive in 6, and unknown
in 2 pts. There are 43 (70.5%) pts alive at a median follow up of
303 (168–560) days. Actuarial estimates of survival at one year are
83% for pts who received MRD transplants and 63% for pts who
received MUD or MMRD transplants. Causes of death include
relapse (n5), aGVHD (n3), multi-organ-system-failure (n3),
pneumonitis (n4, interstitial/CMV/aspergillus), and 1 each of
infection, neurologic toxicity, and arterial thrombosis. Preliminary
results of this study reveal no adverse affects of ECP on regimen
related toxicity or engraftment after a standard myeloablative
AHCT. The overall survival of pts in this trial is encouraging and
warrants further study.
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HUMAN HERPESVIRUS 6 MANIFESTING AS ENCEPHALITIS IN HEMA-
TOPOIETIC PROGENITOR CELL RECIPIENT AFTER REDUCED INTEN-
SITY ALLOGENEIC TRANSPLANTATION
Ng, N.; Devoe, C.; John, V.; Bayer, R.-L. North Shore-LIJ Health
Systems, Manhasset, NY.
Diagnosis of active Human Herpesvirus 6 (HHV-6) infection in
Hematopoietic Progenitor Cell (HPC) recipients can be difﬁcult
because the virus is ubiquitous and persistent in the human body.
HHV-6 infection usually occurs within 2 to 4 weeks following
transplantation. Infection with HHV-6 can be primary infection or
reactivation. Viral infection can result in clinical symptoms includ-
ing fever, rash, pneumonia, bone marrow suppression, encephalitis
and rejection. There is also a possible correlation between graft
versus host disease and HHV-6. We report a case of a 50 year old
male with a history of refractory Acute Myelogenous Leukemia
(AML). The patient was induced with Etoposide, Ara-C and
Daunorubicin. He relapsed despite consolidation chemotherapy
with HiDAC and Etoposide. He underwent other inductions with-
out lasting response. Bone marrow biopsy after Myelotarg and
HiDAC was hypocellular and he was taken directly to transplan-
tation. The patient underwent a 5/6 HLA mismatched sibling
donor transplant. The preparative regimen included Fludarabine
25 mg/m2/d  5, Melphalan 70 mg/m2/d  2 and ATG. His
GVHD prophylaxis included Cyclosporine and Methotrexate. The
patient engrafted on day 23. Donor chimerism was 100% on day
30. Approximately 3 weeks after transplant, the patient developed
fever, severe myoclonus, mental status changes and amnesia. A
brain MRI showed temporal lobe enhancement. Lumbar puncture
revealed total protein of 58 mg/dL, glucose 80 mg/dL, WBC
1/L, and RBC 1940/L. HHV-6 IgG was 1:320 and IgM was
negative prior to transplantation. The patient required intubation
and blood pressure support. He was treated with IVIG weekly and
Acyclovir initially. Multiplex RT-PCR analysis (Argene, Inc.) of
the CSF was positive for HHV-6. The patient was started on
ganciclovir when the data was obtained; however his status had
improved prior to the change in medications. Follow-up HHV-6
titers 4 weeks after decompensation revealed HHV-6 IgG 1:1280.
The patient developed grade 2–3 GVHD of the gut approximately
day 55. Based on the MRI ﬁndings, the PCR positivity of the spinal
ﬂuid and the amnesia, we suspect that this is active HHV-6 infec-
tion. There have been several cases of encephalitis due to HHV-6
in HPC transplant patients who have presented with amnesia and
who have temporal enhancement on MRI. HHV-6 can be a serious
pathogen in HPC recipients receiving reduced-intensity prepara-
tive regimens.
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PERI-TRANSPLANT IMATINIB ADMINISTRATION RESULTS IN SIGNIFI-
CANT MORTALITY OF RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTS DUE TO IMPAIRED BONE MARROW RECOV-
ERY
Keating, A.R.; McGoldrick, S.; Kochman, A.; Eng, J.M.; Hubbard,
V.M.; van den Brink, M.R.M. Memorial Sloan Kettering Cancer Cen-
ter, New York, NY.
Allogeneic hematopoietic stem cell transplantation (HSCT) is
the only known cure for chronic myeloid leukemia (CML). Ima-
tinib mesylate is able to induce a complete hematologic response in
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most patients but less than 5% of patients achieve a molecular
remission. Therefore, combination regimens consisting of alloge-
neic HSCT and imatinib have been proposed. We used murine
models of allogeneic HSCT to investigate the effects of imatinib
administration in the peri-transplant period. We used an MHC-
matched allogeneic HSCT model (B10.BR 3 CBA) and a con-
genic syngeneic HSCT model (Ly5.1 3 B6). All mice received
lethal doses of radiation followed by injection of 5  106 T-cell
depleted bone marrow cells. Imatinib was administered via intra-
peritoneal injection twice daily from day 1 to day 8 of transplant
at a dose of 45 mg/kg/dose. In the congenic model, all imatinib-
treated mice died by day 8 whereas control mice had 100% survival
(combined data of 2 transplants; n16; p
0.0001). Similarly, the
imatinib-treated mice in the allogeneic HSCT model had inferior
survival compared to controls (p0.0001). We analyzed imatinib-
treated allogeneic HSCT recipients on day 14 and found that
thymocyte counts were signiﬁcantly reduced in the imatinib
treated group (0.96  106) compared to controls (8.2  106)
(p
0.00002). The numbers of CD4, CD8 and double positive
thymocytes were also signiﬁcantly reduced. Total splenocyte
counts were diminished in the imatinib-treated group as well, but
the difference was not signiﬁcant (29.8  106 vs. 37.3  106). The
numbers of splenic CD3 T cells, B220 B cells and NK1.1 NK
cells were signiﬁcantly reduced in the imatinib-treated allogeneic
HSCT recipients. We found no differences in the total number of
bone marrow cells or CFU-GM or BFU-E colonies in imatinib-
treated mice versus controls. We performed weekly complete
blood counts and noted signiﬁcant decreases in the hemoglobin
concentration (day 7 and 14), platelets (day 7) and lympho-
cytes (day 21). In conclusion, peri-transplant administration of
imatinib to recipients of a syngeneic or allogeneic T-cell depleted
HSCT results in signiﬁcant mortality, which is associated with
profound defects in T-, B- and NK-lymphopoiesis, as well as
moderate decreases in erythrocyte and platelet recovery.
109
CD4V11 T CELLS EXHIBIT LIMITED TCR- REPERTOIRE DIVER-
SITY IN THE miHA-MATCHED C57BL/6 3 BALB.B MODEL OF GRAFT-
VERSUS-HOST DISEASE
DiRienzo, C.G.; Friedman, T.; Korngold, R. Thomas Jefferson Univer-
sity Kimmel Cancer Center, Philadelphia, PA.
Spectratype analysis of the TCR V chain is a useful tool for
examining the T cell repertoire of clonally expanded populations of
T cells responding to minor histocompatibility antigens (miHAs)
during graft-versus-host disease (GVHD). The nature of miHAs in
the CD4-mediated, H2b-matched C57BL/6 3 BALB.B model
remains elusive, but previous spectratype analysis demonstrated a
vital role for CD4V11 T cells in mediating GVHD. Transfer
of C57BL/6 CD4V11T cells, along with T cell-depleted bone
marrow, caused lethal GVHD in BALB.B mice. The TCR V
chain alone does not determine the speciﬁcity of peptide-MHC
recognition. The speciﬁcity of peptide-MHC recognition is mainly
determined by the CDR1 and CDR3 loops of both the TCR- and
- chains. Evidence from crystallographic studies, TCR- trans-
genic mice, and tumor-reactive T cells from humans showed that
a single TCR- chain could pair with multiple TCR- chains and
still maintain peptide speciﬁcity. These studies suggest that the
TCR- chain may have a predominant role in antigen recognition.
Analysis of the TCR- chain has not been previously examined
using the well-characterized system of spectratype analysis. Upon
transplant of unfractionated C57BL/6 CD4 T cells into lethally
irradiated BALB.B recipients, analysis of the TCR- repertoire
within the BALB.B-reactive CD4V11 C57BL/6 T cell popu-
lation was performed on day 10. Our data show that there is limited
V diversity in the CD4V11 response to BALB.B miHAs. The
limited TCR diversity seen with both the V and V chains
suggests that C57BL/6 CD4 T cells recognize a limited number
of antigenic peptides in this model.
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PURE RED CELL APLASIA (PRCA) FOLLOWING ABO-INCOMPATIBLE
ALLOGENEIC BONE MARROW TRANSPLANTATION
Sethi, S.1,2; Hamadani, M.H.1; Kamble, R.1,2; Kharfan-Dabaja, M.1,2;
Ozer, H.1,2; Selby, G.S.1,2 1. Department of Internal Medicine, Okla-
homa University Health Sciences Center, Oklahoma City, OK; 2. Section
of Hematology and Oncology and Bone Marrow Transplantation, Okla-
homa University Health Sciences Center, Oklahoma City, OK.
Background: Pure red cell aplasia (PRCA) following ABO in-
compatible allogenic BMT has been reported. The treatment of
PRCA varies widely with no clear consensus amongst transplant
institutions. Method: 3 patients were found to have PRCA. Ret-
rospective analysis of patients and treatment characteristics of these
forms the basis of this report. In addition, we provide systemic
review of the treatment of PRCA following allogeneic transplant
from the published literature. Results: All 3-patients had acute
myelogenous leukemia and received graft from ABO incompatible
donor. The median age was 49 years (range  39–62). Condition-
ing and GVHD prophylaxis included, CY/TBI 2, BU/CY1,
Cyclosporine  Methotrexate  3. Median time to PRCA from
the date of transplant was 30 weeks (range 13–32). Two patients
received treatment with prednisone at 1 mg/kg; one patient was
treated with Erythropoietin alone. Median time to respond and
transfusion independence in steroid treated patients was 15 days
(data not available for patient treated with Erythropoietin). Total
of 39 published reports describe 60 patients with PRCA following
ABO mismatch allogeneic transplant. The successful treatment of
PRCA varies widely and include, no treatment (spontaneous res-
olution)  15, Cyclosporine discontinuation 4, tapering of cy-
closporine and onset of GVHD  2, reinstitution of cyclospor-
ine  1, Erythropoietin alone  7, Steroids alone  4, Steroids 
Erythropoietin  1, Plasmapheresis  10, Immuno-adsorption
aphaeresis  4, Antilymphocyte globulin  2, Antithymocyte
globulin 2, Rituximab 2, Donor leukocyte infusion (DLI) 2.
Treatment details were not available in 4 reports. The median time
to response (transfusion independence) is available in 19/60 pa-
tients. Median time to response was higher in patients with DLI
and immunotherapy (observation/erythropoietin/steroids/CSA ta-
pering 56 days, ATG/ALG/Rituximab/DLI 69).Conclusion:
Initial management with observation, cyclosporine tapering, eryth-
ropoietin with or without steroids results in resolution of PRCA in
over 50% patients. Refractory patients should be treated with
plasmapheresis, immuno-adsorption aphaeresis, immunotherapy
(ATG, ALG, Rituximab, DLI) in that order.
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PROGNOSTIC FACTORS FOR ALLOGENEIC STEM CELL TRANSPLANTA-
TION (ASCT) FOR UNTREATED FIRST RELAPSE OF ACUTE MYELOID
LEUKEMIA (AML)/MYELODYSPLASTIC SYNDROME (MDS)
Alamo, J.G.; Shahjahan, M.; Wong, R.S.; de Lima, M.; Khouri, I.;
Gajewski, J.; Couriel, D.; Andersson, B.S.; Anderlini, P.; Champlin, R.;
Giralt, S. University of Texas M.D. Anderson Cancer Center, Houston,
TX.
Introduction: The treatment of patients relapsing after primary
therapy for Acute Myeloid Leukemia or High Risk Myelodysplas-
tic Syndromes is controversial. Although many centers recommend
proceeding to allografting if a donor is available without re-induc-
tion therapy, the data on which this recommendation is based is
limited, because of small numbers and patient heterogeneity.
Methods: To determine potential clinical factors that could allow
physicians to decide which patients with ﬁrst relapse AML/MDS
could beneﬁt or not from re-induction therapy we performed a
retrospective analysis of 81 patients (39 males; 42 females) who
received ASCT for untreated AML after First Relapse (n60),
MDS (n13) and MDS/AML (n8) between 01/1989 and 02/
2003 at M.D. Anderson Cancer Center. Results: Median age was
39 years (range 17–68). The median time interval from diagnosis
to transplant was 0.7 years (range 0.22–4.23). 73 patients received
transplant from related donors (63 siblings, 5 children, 5 parents)
and 8 from matched unrelated donors. Preparative regimens in-
cluded TBI based (n20), FM	 ATG (n10), FB	 ATG, Bu/Cy
(n11), Bu/Cy/TT (n18), BuCyDAC (n2), others (n8).
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